Year in Review

Proceedings from a Multitumor CME Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

CME Information

TARGET AUDIENCE

This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

OVERVIEW OF ACTIVITY

Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a daylong symposium combine the perspectives of 15 renowned investigators with a review of key recent presentations and publications across breast cancer, genitourinary cancers, Hodgkin and non-Hodgkin lymphoma, including chronic lymphocytic leukemia, multiple myeloma, gastrointestinal cancers, dermatologic cancers and non-small cell lung cancer to assist clinicians in the formulation of up-to-date management strategies.

LEARNING OBJECTIVES

- Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
- Compare and contrast the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
- Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
- Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
- Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
- Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
- Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 7.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of video and interactive text components. To receive credit, the participant should watch the video, respond to the interactive poll questions, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/YiRMultitumor15/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee

No relevant conflicts of interest to disclose.

Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina

Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sandoz; **Contracted Research:** Celgene Corporation, Genentech BioOncology, Pfizer Inc.

Howard A Burris III, MD
Chief Medical Officer
Executive Director, Drug Development
Sarah Cannon Research Institute
Nashville, Tennessee

No relevant conflicts of interest to disclose.

Adil Daud, MD
Professor of Medicine
University of California, San Francisco
San Francisco, California

Advisory Committee: Amgen Inc, Genentech BioOncology, GlaxoSmithKline, OncoSec Medical; **Consulting Agreements:** Bristol-Myers Squibb Company, Merck, Novartis Pharmaceuticals Corporation, OncoSec Medical, Takeda Oncology; **Contracted Research:** Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

Charles G Drake, MD, PhD
Co-Director, Multi-D Prostate Cancer Clinic
Professor of Oncology, Urology and Immunology
Johns Hopkins Sidney Kimmel Cancer Center
Baltimore, Maryland

Consulting Agreements: Amplimmune Inc, Bristol-Myers Squibb Company, Compugen, Dendreon Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, ImmuneXcite Inc, ImmuNext Inc, Novartis Pharmaceuticals Corporation, Potenza Therapeutics, Roche Laboratories Inc, Sanofi; **Patents:** Amplimmune Inc, Bristol-Myers Squibb Company, Potenza Therapeutics; **Stock Ownership:** Compugen, ImmuneXcite Inc, ImmuNext Inc.

Michelle A Fanale, MD
Associate Professor
Department of Lymphoma and Myeloma at
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Merck, Spectrum Pharmaceuticals Inc; **Contracted Research:** Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics, Takeda Oncology; **Data and Safety Monitoring Board:** Amgen Inc; **Honoraria:** Merck, Seattle Genetics, Spectrum Pharmaceuticals Inc, Takeda Oncology.

Axel Grothey, MD
Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Celgene Corporation, Genentech BioOncology, Lilly; **Contracted Research:** Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech BioOncology, Lilly, Merck, Sanofi.

Roy S Herbst, MD, PhD
Ensign Professor of Medicine (Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, Connecticut

Advisory Committee: AstraZeneca Pharmaceuticals LP, Biothera, Bristol-Myers Squibb Company, Diatech, Genentech BioOncology, Kolltan Pharmaceuticals Inc, Lilly, NotI Microarrays; **Consulting Agreements:** Merck, Pfizer Inc.

Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
St Louis, Missouri

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Takeda Oncology.

Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania

Advisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc; **Consulting Agreements:** Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Pfizer Inc; **Contracted Research:** Astellas Pharma Global Development Inc, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Merck; **Data and Safety Monitoring Board:** AbbVie Inc, Amgen Inc, Lilly, Peregrine Pharmaceuticals Inc, Synta Pharmaceuticals Corp.

Evan J Lipson, MD
Assistant Professor, Medical Oncology
Melanoma and Cancer Immunology Programs
Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Advisory Committee: Amgen Inc, Castle Biosciences Incorporated; **Consulting Agreements:** Bristol-Myers Squibb Company, Merck.

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Director of Translational Research
B-Cell Malignancy Program
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Sanofi, Takeda Oncology.

Craig Moskowitz, MD
Clinical Director
Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Consulting Agreements: Celgene Corporation, Genentech BioOncology, Merck, Seattle Genetics; **Contracted Research:** Merck, Pharmacyclics Inc, Seattle Genetics.

William K Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M Greenspan, MD Professor in Clinical
Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
Mt Sinai Health System
New York, New York

Advisory Committee: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, DAVA Oncology, Inovio Pharmaceuticals, Janssen Biotech Inc, Sanofi, Seattle Genetics, Teva Oncology.

Ruth O'Regan, MD
Division Head of Hematology and Oncology
Department of Medicine
University of Wisconsin
Madison, Wisconsin

Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc.

S Vincent Rajkumar, MD
Professor of Medicine
Division of Hematology
Chair, Myeloma Amyloidosis Dysproteinemia Group
Mayo Clinic
Rochester, Minnesota

No relevant conflicts of interest to disclose.

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee: Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; **Consulting Agreements:** Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology, TG Therapeutics Inc; **Contracted Research:** Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, Takeda Oncology.

MODERATOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Amgen Inc, Astellas Pharma Global Development Inc/Medivation Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, bioTheranostics Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Merck, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, Prometheus Laboratories Inc, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2016

Expiration date: March 2017

Select Publications

Breast Cancer

Chan A et al. **Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.** Breast Cancer Symposium 2015;**Abstract 117**.

Ellis PA et al. **Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.** *Proc ASCO* 2015;**Abstract 507**.

Gianni L et al. **Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).** *Proc ASCO* 2015;**Abstract 505**.

Harbeck N et al. **Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.** *Proc ASCO* 2015;**Abstract 506**.

Nanda R et al. **A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer.** San Antonio Breast Cancer Symposium 2014;**Abstract S1-09**.

Sanft TB et al. **Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.** *Proc ASCO* 2015;**Abstract 538**.

Sparano JA et al. **Prospective validation of a 21-gene expression assay in breast cancer.** *N Engl J Med* 2015;373(21):2005-14.

Tolaney SM et al. **A phase Ib study of abemaciclib with therapies for metastatic breast cancer.** *Proc ASCO* 2015;**Abstract 522**.

Tolaney SM et al. **Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer.** San Antonio Breast Cancer Symposium 2014;**Abstract P5-19-13**.

Traina TA et al. **Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).** *Proc ASCO* 2015;**Abstract 1003**.

Turner NC et al. **Palbociclib in hormone-receptor-positive advanced breast cancer.** *N Engl J Med* 2015;373(3):209-19.

Turner NC et al. **PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.** *Proc ASCO* 2015;**Abstract LBA502**.

Untch M et al. **A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69.** San Antonio Breast Cancer Symposium 2014;**Abstract PD2-6**.

Zhang Y et al. **Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence.** *Clin Cancer Res* 2013;19(15):4196-205.

Genitourinary Cancers

Antonarakis ES et al. **Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.** *JAMA Oncol* 2015;1(5):582-91.

Antonarakis ES et al. **AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).** Genitourinary Cancers Symposium 2015;**Abstract 138**.

Antonarakis ES et al. **AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.** *N Engl J Med* 2014;371(11):1028-38.

Choueiri TK et al. **Cabozantinib versus everolimus in advanced renal-cell carcinoma.** *N Engl J Med* 2015;373(19):1814-23.

Duchesne GM et al. **TROG 03.06 and VCOG PR 01-03: The "Timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial.** *Proc ASCO* 2015;**Abstract 5007**.

James ND et al. **Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476).** *Proc ASCO* 2015;**Abstract 5001**.

McDermott DF et al. **Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab.** *J Clin Oncol* 2015;33(18):2013-20.

Motzer RJ et al. **Nivolumab versus everolimus in advanced renal-cell carcinoma.** *N Engl J Med* 2015;373(19):1803-13.

Select Publications

Motzer R et al. **Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).** *Proc ASCO* 2015;**Abstract 4506**.

Penson D et al. **A multicenter Phase 2 study of enzalutamide (ENZA) versus bicalutamide (BIC) in men with nonmetastatic (M0) or metastatic (M1) castration-resistant prostate cancer (CRPC): The STRIVE trial.** *Proc AUA* 2015;**Abstract LBA10**.

Petrylak DP et al. **A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).** *Proc ASCO* 2015;**Abstract 4501**.

Plimack ER et al. **Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.** *Proc ASCO* 2015;**Abstract 4502**.

Saad F et al. **Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.** *Proc ASCO* 2015;**Abstract 5034**.

Shore N et al. **Radium-223 dichloride in expanded-access setting in the United States: Overall and concurrent experience with abiraterone or enzalutamide.** *Proc AUA* 2015;**Abstract MP87-12**.

Vogelzang NJ et al. **Radium-223 dichloride (Ra-223) in US expanded access program (EAP).** Genitourinary Cancers Symposium 2015;**Abstract 247**.

Hodgkin and Non-Hodgkin Lymphomas

Advani RH et al. **Two doses of polatuzumab vedotin (PoV, anti-CD79b antibody-drug conjugate) in patients (pts) with relapsed/refractory (RR) follicular lymphoma (FL): Durable responses at lower dose level.** *Proc ASCO* 2015;**Abstract 8503**.

Ansell SM et al. **PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.** *N Engl J Med* 2015;372(4):311-9.

Chanan-Khan AAA et al. **Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.** *Proc ASCO* 2015;**Abstract LBA7005**.

Dreyling M et al. **Phase 2A study of copanlisib, a novel PI3K inhibitor, in patients with indolent lymphoma.** *Proc ASH* 2014;**Abstract 1701**.

Dupuis J et al. **Final analysis of the RO-CHOP Phase Ib/II study: Romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL).** *Proc ASH* 2014;**Abstract 504**.

Eichhorst B et al. **Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study).** *Proc ASH* 2014;**Abstract 19**.

Farooqui MZ et al. **Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial.** *Lancet Oncol* 2015;16(2):169-76.

Goede V et al. **Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: Results of the CLL11 study.** *Proc ASH* 2014;**Abstract 3327**.

Jacobsen ED et al. **Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.** *Blood* 2015;125(9):1394-402.

Kochenderfer JN et al. **Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.** *J Clin Oncol* 2015;33(6):540-9.

Le Gouill S et al. **Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: First interim analysis of the Phase III prospective Lyma trial, a Lysa study.** *Proc ASH* 2014;**Abstract 146**.

Leonard JP et al. **Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance).** *J Clin Oncol* 2015;33(31):3635-40.

Moskowitz AJ et al. **PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosfamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study.** *Lancet Oncol* 2015;16(3):284-92.

Select Publications

Moskowitz CH et al. **Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet* 2015;385(9980):1853-62.

Moskowitz CH et al. **PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a Phase 1b study (KEYNOTE-013).** *Proc ASH* 2014;Abstract 290.

Nowakowski GS et al. **Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase II study.** *J Clin Oncol* 2015;33(3):251-7.

Nowakowski GS et al. **Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.** *Proc ASCO* 2015;**Abstract TPS8600**.

Robak T et al. **Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.** *N Engl J Med* 2015;372(10):944-53.

Salles GA et al. **Idelalisib efficacy and safety in follicular lymphoma patients from a phase 2 study.** *Proc ASCO* 2015;**Abstract 8529**.

Sehn LH et al. **GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.** *Proc ASCO* 2015;**Abstract LBA8502**.

Walewski JA et al. **Multivariate analysis of PFS from the AETHERA trial: A phase III study of brentuximab vedotin consolidation after autologous stem cell transplant for HL.** *Proc ASCO* 2015;**Abstract 8519**.

Multiple Myeloma

Berdeja JG et al. **A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).** *Proc ASCO* 2015;**Abstract 8513**.

Dimopoulos MA et al. **Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR.** *Proc ASCO* 2015;**Abstract 8509**.

Kumar S et al. **Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): Phase 2 study results.** *Proc ASH* 2014;**Abstract 82**.

Kumar SK et al. **Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study.** *Lancet Oncol* 2014;15(13):1503-12.

Lonial S et al. **Elotuzumab therapy for relapsed or refractory multiple myeloma.** *N Engl J Med* 2015;373(7):621-31.

Lonial S et al. **Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).** *Proc ASCO* 2015;**Abstract LBA8512**.

Rosenthal AC et al. **The cardiovascular impact of carfilzomib in multiple myeloma.** *Proc ASH* 2014;**Abstract 4748**.

Stewart AK et al. **Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.** *N Engl J Med* 2015;372(2):142-52.

Straka C et al. **Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).** *Proc ASCO* 2015;**Abstract 8511**.

Vij R et al. **Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): Updated results from a multicenter, open-label, dose escalation Phase 1b/2 study.** *Proc ASH* 2014;**Abstract 34**.

Zimmerman TM et al. **Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).** *Proc ASCO* 2015;**Abstract 8510**.

Colorectal, Gastric and Pancreatic Cancer

Bang YJ et al. **Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.** *Proc ASCO* 2015;**Abstract 4001**.

Select Publications

Chen LT et al. **Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.** Gastrointestinal Cancers Symposium 2015;**Abstract 234**.

Hurwitz H et al. **JANUS 1: A phase 3, placebo-controlled study of ruxolitinib plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) after failure or intolerance of first-line chemotherapy.** *Proc ASCO* 2015;**Abstract TPS4147**.

Hurwitz HI et al. **Randomized, double-blind, Phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed.** *J Clin Oncol* 2015;33(34):4039-47.

Katz MHG et al. **Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101.** *Proc ASCO* 2015;**Abstract 4008**.

Le DT et al. **PD-1 blockade in tumors with mismatch-repair deficiency.** *N Engl J Med* 2015;372(26):2509-20.

Le DT et al. **PD-1 blockade in tumors with mismatch repair deficiency.** *Proc ASCO* 2015;**Abstract LBA100**.

Ng K et al. **Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).** *Proc ASCO* 2015;**Abstract 3503**.

O'Reilly EM et al. **JANUS 2: A phase III study of survival, tumor response, and symptom response with ruxolitinib plus capecitabine or placebo plus capecitabine in patients with advanced or metastatic pancreatic cancer (mPC) who failed or were intolerant to first-line chemotherapy.** *Proc ASCO* 2015;**Abstract TPS4146**.

Shah MA et al. **The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.** *Proc ASCO* 2015;**Abstract TPS4139**.

Siena S et al. **Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.** *Proc ASCO* 2015;**Abstract 3508**.

Tabernero J et al. **Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study.** *Lancet Oncol* 2015;16(5):499-508.

Van Cutsem E et al. **Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer.** ESMO World Congress on Gastrointestinal Cancers 2015;**Abstract LBA-05**.

Van Cutsem E et al. **TAS-102 vs placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the RECOURSE trial.** *Proc ASCO* 2015;**Abstract 3595**.

Dermatologic Cancers

Daud A et al. **Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.** *Proc ASCO* 2015;**Abstract 9005**.

Dummer R et al. **Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the STEVIE study.** *Proc ASCO* 2015;**Abstract 9024**.

Larkin J et al. **Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.** *N Engl J Med* 2015;373(1):23-34.

Larkin JMG et al. **Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced *BRAF*-mutated melanoma.** *Proc ASCO* 2015;**Abstract 9006**.

Long GV et al. **Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial.** *Lancet* 2015;386(9992):444-51.

Migden MR et al. **Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial.** *Lancet Oncol* 2015;16(6):716-28.

Postow MA et al. **Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.** *N Engl J Med* 2015;372(21):2006-17.

Robert C et al. **Pembrolizumab versus ipilimumab in advanced melanoma.** *N Engl J Med* 2015;372(26):2521-32.

Select Publications

Wolchok JD et al. **Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.** *Proc ASCO* 2015;**Abstract 3000**.

Wolchok JD et al. **Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).** *Proc ASCO* 2015;**Abstract LBA1**.

Non-Small Cell Lung Cancer

Borghaei H et al. **Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.** *N Engl J Med* 2015;373(17):1627-39.

Brahmer J et al. **Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.** *N Engl J Med* 2015;373(2):123-35.

Drilon A et al. **Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches.** *Clin Cancer Res* 2015;21(16):3631-9.

Drilon AE et al. **Phase II study of cabozantinib for patients with advanced *RET*-rearranged lung cancers.** *Proc ASCO* 2015;**Abstract 8007**.

Felip E et al. **ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).** *Proc ASCO* 2015;**Abstract 8060**.

Garon EB et al. **Pembrolizumab for the treatment of non-small-cell lung cancer.** *N Engl J Med* 2015;372(21):2018-28.

Gerber DE et al. **ALCHEMIST: A clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.** *Proc ASCO* 2015;**Abstract TPS7583**.

Langer CJ et al. **Weekly *nab*-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Analysis of safety and efficacy in patients with renal impairment.** *Clin Lung Cancer* 2015;16(2):112-20.

Lee CK et al. **Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: A meta-analysis.** *J Clin Oncol* 2015;33(17):1958-65.

Ou SHI et al. **Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).** *Proc ASCO* 2015;**Abstract 8008**.

Paik PK et al. **Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.** *Cancer Discov* 2015;5(8):842-9.

Paz-Ares L et al. **Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).** *Proc ASCO* 2015;**Abstract LBA109**.

Planchard D et al. **Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with *BRAF* V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).** *Proc ASCO* 2015;**Abstract 8006**.

Ramalingam SS et al. **AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for *EGFR* mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.** *Proc ASCO* 2015;**Abstract 8000**.

Rizvi NA et al. **Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC).** *Proc IASLC* 2015;**Abstract ORAL02.05**.

Senan S et al. **Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).** *Proc ASCO* 2015;**Abstract 7506**.

Sequist LV et al. **Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).** *Proc ASCO* 2015;**Abstract 8001**.

Soria J-C et al. **Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).** *Proc ASCO* 2015;**Abstract 8002**.

Select Publications

Soria JC et al. **Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial.** *Lancet Oncol* 2015;16(8):990-8.

Spigel D et al. **A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).** *Proc ASCO* 2015;**Abstract 8009**.

Thatcher N et al. **Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial.** *Lancet Oncol* 2015;16(7):763-74.